Related Experiment Video

Updated: Jun 11, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

GABA(A) Receptor Activation Drives GABARAP-Nix Mediated Autophagy to Radiation-Sensitize Primary and Brain-Metastatic

Debanjan Bhattacharya1, Riccardo Barrile2, Donatien Kamdem Toukam1

  • 1Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.

Cancers
|September 28, 2024
PubMed

Insights

AM-101, a GABA(A) receptor activator, shows promise in non-small cell lung cancer (NSCLC) treatment by impairing tumor cell growth and potentiating radiation therapy. This approach may enhance tumor control and reduce toxicity in NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Radiotherapy for non-small cell lung cancer (NSCLC) has limitations due to non-durable responses and toxicity.
  • Novel therapeutic strategies are needed to improve treatment efficacy and patient outcomes in advanced NSCLC.

Purpose of the Study:

  • To investigate the efficacy of AM-101, a GABA(A) receptor activator, in non-small cell lung cancer (NSCLC).
  • To elucidate the molecular mechanisms underlying AM-101's anti-cancer effects.
  • To evaluate AM-101's potential to enhance radiotherapy in NSCLC treatment.

Main Methods:

  • In vitro studies using primary and brain-metastatic NSCLC cell lines.
  • Ex vivo drug efficacy testing on a human-relevant 'chip' model.
  • In vivo studies using mouse models with intracranial NSCLC tumors.
  • Molecular analyses of autophagy-related protein interactions (GABARAP, Nix, p62).

Main Results:

  • AM-101 significantly impaired NSCLC cell viability and clonogenicity.
  • AM-101 demonstrated comparable efficacy to docetaxel in ex vivo models.
  • AM-101 potentiated radiation therapy in vivo, improving survival in mice with brain metastases.
  • GABA(A) receptor activation triggers a specific autophagic pathway involving GABARAP-Nix multimerization.

Conclusions:

  • AM-101 is a potent anti-cancer agent against NSCLC, including brain metastases.
  • The GABARAP-Nix-mediated autophagy pathway is crucial for AM-101's cytotoxicity.
  • AM-101 holds potential as a therapeutic agent to enhance radiotherapy efficacy and reduce toxicity in NSCLC patients.
Keywords:
GABA receptorGABARAPNixautophagybenzodiazepinebrain metastasislung cancerp62radiotherapy

More Related Videos

Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking11:57

Using an α-Bungarotoxin Binding Site Tag to Study GABA A Receptor Membrane Localization and Trafficking

Published on: March 28, 2014

15.8K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.5K

Related Concept Videos

GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.9K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.3K
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
6.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
152